Valuation: Profound Medical Corp.

Market Cap 349M 249M 218M 201M 185M 23.98B 357M 2.4B 944M 11.74B 935M 915M 40.43B P/E 2026 *
-8.22x
P/E 2027 * -9.24x
Enterprise Value 349M 249M 218M 201M 185M 23.98B 357M 2.4B 944M 11.74B 935M 915M 40.43B EV / Sales 2026 *
9.69x
EV / Sales 2027 * 5.71x
Free-Float
95.93%
Yield 2026 *
-
Yield 2027 * -
1 day+0.63%
1 week-4.48%
Current month+1.80%
1 month-0.41%
3 months+5.26%
6 months-17.38%
Current year-10.86%
1 week 9.31
Extreme 9.31
10.24
1 month 8.95
Extreme 8.95
11.2
Current year 6.52
Extreme 6.52
12.4
1 year 5.23
Extreme 5.23
12.4
3 years 5.23
Extreme 5.23
17.02
5 years 4.21
Extreme 4.21
22.63
10 years 4.21
Extreme 4.21
36.73
Manager TitleAgeSince
Chief Executive Officer 71 2016-08-14
President 44 2024-11-06
Director of Finance/CFO 58 2022-03-02
Director TitleAgeSince
Chairman 71 -
Director/Board Member 68 2018-06-13
Director/Board Member 79 2018-06-13
Date Insider Type Main position Quantity % Market Cap.
6/29/26 Option

Director

2,122 0.0058%
6/29/26 Option

Director

1,763 0.0049%
6/29/26 Option

Director

1,762 0.0048%
Change 5-day change 1-year change 3-year change Capi.($)
+0.63%-4.48%+25.33%-43.50% 249M
-1.97%+1.03%+28.39%+1.68% 198B
-0.58%+2.40%+7.25%-15.35% 144B
-14.15%-15.08%-33.40%-2.68% 122B
-1.32%-1.65%-57.52%-16.63% 65.44B
-2.40%-7.03%+12.08%-6.81% 49.36B
-0.11%+1.53%-23.83%-30.51% 44.75B
-3.41%-2.11%+15.33%+9.95% 37.13B
-2.44%-1.98%+28.33%+35.71% 36.23B
-4.00%-2.52%-16.97%-23.52% 28.69B
Average -2.98%-2.51%-1.50%-9.16% 72.63B
Weighted average by Cap. -3.78%-1.83%-0.75%-5.54%

Financials

2026 *2027 *
Net sales 35.99M 25.69M 22.45M 20.71M 19.09M 2.47B 36.79M 248M 97.38M 1.21B 96.47M 94.35M 4.17B 61.07M 43.59M 38.09M 35.15M 32.4M 4.2B 62.43M 420M 165M 2.06B 164M 160M 7.08B
Net income -43.34M -30.94M -27.03M -24.95M -22.99M -2.98B -44.3M -298M -117M -1.46B -116M -114M -5.02B -40.95M -29.23M -25.54M -23.57M -21.73M -2.81B -41.86M -282M -111M -1.38B -110M -107M -4.75B
Net Debt - -
Logo Profound Medical Corp.
Profound Medical Corp. is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
Employees
162
Date Price Change Volume
26-07-17 $9.600 +0.63% 2,801
26-07-16 $9.540 -3.05% 17,289
26-07-15 $9.840 -1.40% 11,730
26-07-14 $9.980 -1.77% 13,450
26-07-13 $10.16 +1.09% 12,740
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
9.600
Average target price
-

Quarterly revenue - Rate of surprise